Medical Therapy for Obesity
- 1 September 2010
- journal article
- review article
- Published by Wiley in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Vol. 77 (5) , 407-417
Abstract
Obesity results from a prolonged small positive energy imbalance, and treatment needs to reverse this imbalance. Many different diets have been tried to treat obesity, and weight loss occurs with all of them. There is currently no evidence that supports the superiority of one macronutrient composition for diets over any other. The principal effect seems to be the degree of adherence to the prescribed calorie reduction. Obesity drugs have been developed that tap brain mechanisms for controlling feeding and the gastrointestinal tract and its peptides. Orlistat blocks intestinal lipase and produces modest weight loss. Sibutramine is a serotonin‐norepinephrine reuptake inhibitor that has a warning on its label from the US Food and Drug Administration because of cardiovascular risk. Its marketing has been suspended in Europe. Several drug combinations are on the horizon for treatment of obesity.Mt Sinai J Med 77:407–417, 2010.. © 2010 Mount Sinai School of MedicineKeywords
This publication has 46 references indexed in Scilit:
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 DiabetesThe American Journal of Medicine, 2010
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity PharmacotherapyObesity, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Comparative Study of the Effects of a 1-Year Dietary Intervention of a Low-Carbohydrate Diet Versus a Low-Fat Diet on Weight and Glycemic Control in Type 2 DiabetesDiabetes Care, 2009
- Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and CarbohydratesNew England Journal of Medicine, 2009
- Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietNew England Journal of Medicine, 2008
- Serotonin 5-HT2C Receptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 ReceptorsEndocrinology, 2007
- Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997